Matches in SemOpenAlex for { <https://semopenalex.org/work/W2402887955> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2402887955 endingPage "62" @default.
- W2402887955 startingPage "355" @default.
- W2402887955 abstract "Treatment with zidovudine has been standard therapy for patients with advanced HIV infection, but intolerance is common. Previously, management of intolerance has consisted of symptomatic therapy, dose interruption/discontinuation, and, when appropriate, transfusion. The availability of new antiretroviral agents such as didanosine as well as adjunctive recombinant hematopoietic growth factors makes additional strategies possible for the zidovudine-intolerant patient. Because all of these agents are costly, we evaluated the cost implications of these various strategies for the management of zidovudine-intolerant individuals within a population of persons with advanced HIV disease. We performed a decision analysis using iterative algorithmic models of 1 year of antiretroviral care under various strategies. The real costs providing antiretroviral therapy were estimated by deflating medical center charges by specific Medi-Cal (Medicaid) charge-to-payment ratios. Clinical data were extracted from the medical literature, product package inserts, investigator updates, and personal communications. Sensitivity analysis was used to test the effect of error in the estimation of parameters. The models predict that a strategy of dose interruption and transfusion for zidovudine intolerance will provide an average of 46 weeks of therapy per year to the average patient at a cost of $5,555/year of therapy provided (1991 U.S. dollars). The models predict that a strategy of adding hematopoietic growth factors to the regimen of appropriate patients would increase the average amount of therapy provided to the average patient by 3 weeks (6%) and the costs attributable to therapy by 77% to $9,805/year of therapy provided.(ABSTRACT TRUNCATED AT 250 WORDS)" @default.
- W2402887955 created "2016-06-24" @default.
- W2402887955 creator A5043909785 @default.
- W2402887955 creator A5062321882 @default.
- W2402887955 creator A5088678464 @default.
- W2402887955 date "1994-04-01" @default.
- W2402887955 modified "2023-09-23" @default.
- W2402887955 title "A cost analysis of approved antiretroviral strategies in persons with advanced human immunodeficiency virus disease and zidovudine intolerance." @default.
- W2402887955 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7510808" @default.
- W2402887955 hasPublicationYear "1994" @default.
- W2402887955 type Work @default.
- W2402887955 sameAs 2402887955 @default.
- W2402887955 citedByCount "7" @default.
- W2402887955 countsByYear W24028879552014 @default.
- W2402887955 crossrefType "journal-article" @default.
- W2402887955 hasAuthorship W2402887955A5043909785 @default.
- W2402887955 hasAuthorship W2402887955A5062321882 @default.
- W2402887955 hasAuthorship W2402887955A5088678464 @default.
- W2402887955 hasConcept C126322002 @default.
- W2402887955 hasConcept C160735492 @default.
- W2402887955 hasConcept C162324750 @default.
- W2402887955 hasConcept C177713679 @default.
- W2402887955 hasConcept C187212893 @default.
- W2402887955 hasConcept C203014093 @default.
- W2402887955 hasConcept C2776534028 @default.
- W2402887955 hasConcept C2777447569 @default.
- W2402887955 hasConcept C2778715236 @default.
- W2402887955 hasConcept C2780216070 @default.
- W2402887955 hasConcept C2780727368 @default.
- W2402887955 hasConcept C2781413609 @default.
- W2402887955 hasConcept C2908647359 @default.
- W2402887955 hasConcept C3013748606 @default.
- W2402887955 hasConcept C50522688 @default.
- W2402887955 hasConcept C535046627 @default.
- W2402887955 hasConcept C71924100 @default.
- W2402887955 hasConcept C99454951 @default.
- W2402887955 hasConceptScore W2402887955C126322002 @default.
- W2402887955 hasConceptScore W2402887955C160735492 @default.
- W2402887955 hasConceptScore W2402887955C162324750 @default.
- W2402887955 hasConceptScore W2402887955C177713679 @default.
- W2402887955 hasConceptScore W2402887955C187212893 @default.
- W2402887955 hasConceptScore W2402887955C203014093 @default.
- W2402887955 hasConceptScore W2402887955C2776534028 @default.
- W2402887955 hasConceptScore W2402887955C2777447569 @default.
- W2402887955 hasConceptScore W2402887955C2778715236 @default.
- W2402887955 hasConceptScore W2402887955C2780216070 @default.
- W2402887955 hasConceptScore W2402887955C2780727368 @default.
- W2402887955 hasConceptScore W2402887955C2781413609 @default.
- W2402887955 hasConceptScore W2402887955C2908647359 @default.
- W2402887955 hasConceptScore W2402887955C3013748606 @default.
- W2402887955 hasConceptScore W2402887955C50522688 @default.
- W2402887955 hasConceptScore W2402887955C535046627 @default.
- W2402887955 hasConceptScore W2402887955C71924100 @default.
- W2402887955 hasConceptScore W2402887955C99454951 @default.
- W2402887955 hasIssue "4" @default.
- W2402887955 hasLocation W24028879551 @default.
- W2402887955 hasOpenAccess W2402887955 @default.
- W2402887955 hasPrimaryLocation W24028879551 @default.
- W2402887955 hasRelatedWork W15286642 @default.
- W2402887955 hasRelatedWork W1993848347 @default.
- W2402887955 hasRelatedWork W1995199997 @default.
- W2402887955 hasRelatedWork W2025695342 @default.
- W2402887955 hasRelatedWork W2040582663 @default.
- W2402887955 hasRelatedWork W2072631376 @default.
- W2402887955 hasRelatedWork W2074165008 @default.
- W2402887955 hasRelatedWork W2402887955 @default.
- W2402887955 hasRelatedWork W2463503935 @default.
- W2402887955 hasRelatedWork W809832044 @default.
- W2402887955 hasVolume "7" @default.
- W2402887955 isParatext "false" @default.
- W2402887955 isRetracted "false" @default.
- W2402887955 magId "2402887955" @default.
- W2402887955 workType "article" @default.